Table 3.

Clinical responder and UPCR reduction from baseline by 30% and 50%

Clinical responder (UPCR <0.5 mg/mg), n (%)
Analysis visit	UPCR, mg/mg	C3G (n = 8)
Baseline	≥0.5	8 (100)
Week 48	<0.5	2 (25.0)
	≥0.5	5 (62.5)

UPCR reduction from baseline by 30% and 50%, n (%)
Analysis visit	UPCR reduction from baseline	C3G (n = 8)
Week 48	<30%	1 (12.5)
	≥30%	6 (75.0)
	<50%	4 (50.0)
	≥50%	3 (37.5)

C3G, C3 glomerulopathy; UPCR, urine protein-to-creatinine ratio.

Sample size n = 8 at baseline and n = 7 at week 48 due to 1 participant who stopped study drug at week 24.